


### Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

#### Listing of Claims:

1. (Currently Amended)


An indole compound represented by the formula (I), or a pharmaceutically acceptable salt, solvate, or prodrug thereof;



wherein;

$R_1$  is the group  $-(L_1)-R_{11}$ ; where,  $-(L_1)-$  is an alkylene chain of 1 to 8 carbon atoms and where  $R_{11}$  is  $(CH_2)_m R_{12}$ ;

$m$  is an integer from 1 to 6;



$n$  is an integer from 0 to 2;


$R_{13}$  is selected from  $C_1$  to  $C_8$  alkyl;

$p$  is an integer from 0 to 2;


$R_2$  is hydrogen, or a  $C_1$ - $C_4$  alkyl;

$R_3$  is  $-(L_3)-Z$ , where  $-(L_3)-$  is a bond,

and  $Z$  is the group represented by the formulae,




R<sub>4</sub> is the group, -(L<sub>h</sub>)-(hydroxyfunctional amide); wherein -(L<sub>h</sub>)-, is represented by the formula



Q<sub>2</sub> is -O-;

R<sub>40</sub> is independently selected from hydrogen and C<sub>1</sub>-C<sub>8</sub> alkyl;




Hydroxy functional amide is the group

R<sub>4a</sub> is OH;

R<sub>4b</sub> is selected from hydrogen or C<sub>1</sub>-C<sub>8</sub> alkyl;

R<sub>5</sub> is the group, -(L<sub>a</sub>)-(acidic group); wherein -(L<sub>a</sub>)-, is



R<sub>54</sub> and R<sub>55</sub> are each independently hydrogen or C<sub>1</sub>-C<sub>8</sub> alkyl;


(acidic group) is  $-\text{CO}_2\text{H}$ ;

$\text{R}_6$  and  $\text{R}_7$  are each independently selected from hydrogen,  $\text{C}_1\text{-C}_6$  alkyl,  $\text{C}_2\text{-C}_6$  alkenyl, and  $\text{C}_2\text{-C}_6$  alkynyl.


2. (Previously Presented) The compound of claim 1 wherein  $\text{R}_2$  is  $\text{C}_1\text{-C}_4$  alkyl.

3. (Canceled)

4. (Original) The compound of Claim 1 wherein the hydroxyfunctional amide linker group,  $-(\text{Lh})-$ , for  $\text{R}_4$  is a divalent group selected from,




5. (Previously Presented) The compound of Claim 1 wherein the acid linker,  $-(\text{La})-$ , for  $\text{R}_5$  is the group represented by the formula;




wherein  $\text{R}_{54}$ , and  $\text{R}_{55}$ , are both hydrogen.

6. (Previously Presented) The compound of claim 1 wherein  $\text{R}_5$  is the group,  $-(\text{La})$ -(acidic group) and wherein the (acidic group) is the group:



- 7. (Canceled)
- 8. (Canceled)
- 9. (Canceled)
- 10. (Canceled)
- 11. (Canceled)
- 12. (Canceled)
- 13. (Canceled)
- 14. (Canceled)
- 15. (Canceled)
- 16. (Canceled)
- 17. (Canceled)

18. (Previously Presented) The compound of claim 1 wherein R<sub>4</sub> is the group, -(L<sub>C</sub>)-(hydroxyfunctional amide group) and wherein the (hydroxyfunctional amide group) is:



and R<sup>4a</sup> is the group OH; and  
wherein R<sup>4b</sup> is (C<sub>1</sub>-C<sub>6</sub>)alkyl.

- 19. (Canceled)
- 20. (Canceled)
- 21. (Canceled)

22. (Original) A pharmaceutical formulation comprising a indole compound as claimed in claim 1 together with a pharmaceutically acceptable carrier or diluent therefor.

23. (Canceled)

24. (Previously Presented) A method of treating rheumatoid arthritis in a mammal wherein the method comprises administering to said mammal a therapeutically effective amount of an indole compound as claimed in Claim 1.

25. (Canceled)

26. (Canceled)

27. (Canceled)